We previously demonstrated that recombinant adeno-associated virus vectors based on serotype 2 (rAAV2) can direct transgene expression in salivary gland cells in vitro and in vivo. However, it is not known how other rAAV serotypes perform when infused into salivary glands. The capsids of serotypes 4 and 5 are distinct from rAAV2 and from each other, suggesting that they may direct binding and entry into different cell types. In the present study, we investigated the tropisms, transduction efficiencies, and antibody response to AAV vectors based on AAV serotypes 2, 4, and 5. Administration of rAAV2b-galactosidase (bgal), rAAV4b gal, or rAAV5bgal to murine submandibular salivary glands by retrograde ductal instillation resulted in efficient transduction of salivary epithelial cells, with AAV4 and AAV5 producing 2.3 and 7.3 times more bgal activity compared with AAV2. Improved transduction with AAV5 was confirmed by QPCR of DNA extracted from glands and immunohistochemical staining for transgene expression. Like AAV2, AAV5 primarily transduced striated and intercalated ductal cells. AAV4 transduction was evident in striated, intercalated, and excretory ductal cells, as well as in convoluted granular tubules. In keeping with the encapsulated nature of the salivary gland, the majority of persistent viral genomes were found in the gland and not in other tissues. Neutralizing antibodies (NABs) found in the serum of virus-infused animals were serotype specific and there was no crossreactivity between serotypes. No NABs were detected in saliva but sialic acid conjugates present in saliva could neutralize AAV4 at low dilutions. Together our data suggest that because of differences in receptor binding and transduction pathways, other serotypes may have improved utility as gene transfer vectors in the salivary gland and these differences could be exploited in gene therapy applications. Gene Therapy (2006) 13, 594-601.
Introduction
Vector-mediated gene transfer is a promising approach for the treatment of the pathological consequences of autoimmune disease-and irradiation-induced damage to the salivary glands (for review see Baum et al. 1 and Zufferey and Aebischer 2 ). Development of intraductal cannulation methods allows for easy delivery of vectors to the luminal membranes of almost every parenchymal cell in the salivary glands. Accordingly, a variety of vectors have been examined for in vivo gene transfer activity to the salivary gland. Recombinant adenoviral vectors delivered to the lumen of the glands produce transient, but high-level gene expression. 3 Long-term expression with a modified recombinant adenoviral vector containing retrovirus elements also has been reported. 4 Adeno-associated viruses (AAVs) are small nonpathogenic members of the Parvoviridae family, and are helper virus dependent for replication (see for review Carter 5 ) (genus Dependoviridae). To date, several distinct AAV serotypes have been isolated with AAV2 being the most extensively studied. Recombinant AAV 2 (rAAV2)-based vectors can transduce both dividing and nondividing cells in vitro and in vivo, and maintain high levels of expression of the delivered gene. In contrast to adenoviral vectors, rAAV2 transduction is associated with only a mild immune response. 6, 7 We previously reported that rAAV2 vectors can transduce ductal cells in the murine salivary glands and direct the synthesis of both cellular proteins (aquaporin 1) and secreted proteins such as erypthropoietin. 8, 9 The latter is secreted via the constitutive pathway into the blood. Salivary glands can also be engineered to produce human growth hormone that is secreted via the regulated pathway into saliva. 10 These studies support salivary glands as a potentially useful target site for both local and systemic therapies.
Other isolates of AAV have demonstrated distinct tissue tropisms compared to AAV2 and in several examples improved transduction activity. [11] [12] [13] [14] Efficient AAV2 transduction requires expression of heparan sulfate proteoglycan (HSPG) on the target cell surface. 15 Proteins thought to be involved in AAV2 transduction include fibroblast growth factor receptor 1, a v b 5 integrins, and hepatocyte growth factor receptor. [16] [17] [18] [19] Characterization of the cellular components required for transduction with AAV4 and AAV5 demonstrate that both serotypes preferentially bind to 2-3 sialic acid residues but differ in their linkage specificity. AAV4 requires an O-linked form of sialic acid while AAV5 requires an N-linked form. 20 In addition, platelet-derived growth factor receptors PDGFRa and PDGFRb have been identified as protein receptors for AAV5 and their expression correlates with transduction in vivo.
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In this study, we examined the tissue tropism and transduction activity of two alternative serotypes of AAV (AAV4 and AAV5) compared with AAV2 following retrograde delivery to the submandibular gland of mice. We observed that of the three viruses, AAV5 was the most effective at transducing both striated and intercalated ductal cells while AAV4 displayed an intermediate level of transduction and transduced striated and intercalated ducts, as well as convoluted granular tubules.
Results

rAAV transduction of salivary glands
To compare overall transduction activity, male BALB/c mice received 10 10 particles of rAAV2b-galactosidase (bgal), rAAV4bgal, or rAAV5bgal into the submandibular glands by retrograde ductal administration. To assess reporter-gene expression of the different vectors, whole glands were collected 4 weeks after infusion, homogenized, then analyzed for bgal activity with an ELISA assay specific for the bacterial form of bgal expressed by the AAV vectors ( Figure 1a) . Vector genome copy number in each gland was determined by quantitative PCR (QPCR) (Figure 1b) . Eight out of nine of the glands receiving rAAV2 were positive for bgal activity compared with four out of four for AAV4, and in five out of six for AAV5 (Figure 1a) . Comparison of mean values of bgal activity from the positive animals, indicated that AAV4 and AAV5 vectors directed 2.3-and 7.3-fold higher levels of expression compared with rAAV2. QPCR analysis of the positive salivary glands also confirmed the elevated transduction activity with AAV4 and AAV5 vectors compared with AAV2. Comparison of the mean values of the positive animals indicated that gene transfer with AAV4 and AAV5 vectors resulted in 9.4-and 26-fold increase in vector genomes/100 ng of extracted DNA, respectively, compared with AAV2 ( Figure 1b) . These results suggest that AAV4 and AAV5 vectors maybe more effective gene transfer vectors for the submandibular gland.
Characterization of rAAV-transduced cells
Mouse salivary glands contain multiple epithelial cell types including acinar and various ductal cells as well as specialized ductal cells termed convoluted granular tubules that produce epidermal and nerve growth factors. The ducts terminate in acinar cells (secretory endpieces) that are responsible for secretion of water, electrolytes, and most protein components of saliva. The saliva then flows through the ducts, which are formed by a near-monolayer of epithelial cells, and exits into the mouth (for sketch see Figure 2 ). Our previous work demonstrated that AAV2 infused into the gland preferentially transduced striated and intercalated ductal cells. 9, 22 To determine the cell tropism of AAV4 and AAV5, mice were infused with 10 10 particles of AAV vector encoding a nuclear localized green fluorescent protein (GFP) expression cassette and glands were removed after 6 weeks, sectioned, and analyzed by immunohistochemical staining for GFP expression. In agreement with our earlier work, AAV2 again preferentially transduced striated and intercalated ductal cells in the gland (Figure 2a) . Interestingly, AAV5 also targeted striated and intercalated ductal cells (Figure 2e ), as well as excretory ductal cells (Figure 2f ). In agreement with the bgal data present in Figure 1 , the number of GFP-positive cells/duct was higher with AAV5-infused animals compared with those administered AAV2 (46 and 27%, respectively) ( Table 1) . While the bgal expression following AAV4 transduction was intermediate compared with AAV2 and AAV5, AAV4 had a distinct transduction profile compared with the other serotypes. Whereas AAV4 also transduced both striated, intercalated and excretory ductal cells, it was the only vector to transduce convoluted granular tubule cells (Figure 2b d, Table 1 ). No acinar cells were transduced with any of these vectors. Thus, by using either AAV4 or AAV5 vectors, it is possible to increase gene transfer to murine salivary glands.
Biodistribution of rAAV following retrograde ductal administration
Following infusion of a similar particle dose of adenovirus into salivary glands, vector genomes can be Enhanced transduction of mouse salivary glands H Katano et al detected throughout the animal. 23 However, this was only transient and persistent genomes in nonoral tissue were only infrequently detected by day 15 postinfusion. To examine the persistence of the AAV vector genomes in the gland and assess the potential for spread to other tissues, we performed QPCR analysis of vector DNA extracted from salivary glands, lung, and liver of rAAV2, 4, 5bgal vector treated mice 1-month postinfusion ( Figure 3 ). Protein extracts made from samples of the glands from all animals were tested for bgal activity prior to QPCR analysis to confirm successful gene transfer (data not shown). Previous work with AAV2 had demonstrated that the majority of the persistent viral genomes remained in the gland. 9, 24 Similarly, 490% of the AAV2 persistent genomes were found in the gland, while for AAV4 and AAV5, 499% of the infused virus remained in the gland and was not detected in other tissues. No significant differences in AAV4 or AAV5 distribution in liver and lung were noted when compared with AAV2.
Virus-neutralizing activity in sera
The immune response to an antigen is affected by the route of administration. Previous studies have indicated that delivery of rAAV2 vectors via, intramuscular (i.m.) or intranasal routes leads to relatively mild host immune responses. 7, [25] [26] [27] Salivary glands are part of the mucosal immune system. Therefore, we assayed for the presence of neutralizing antibodies (NABs) in the serum of mice 1-month postretroductal infusion of AAVbgal vectors. Serotype-specific NABs were detected with all three vectors following infusion ( Figure 4 ). The NAB titer, the dilution at which 50% of the vector transduction is inhibited, differed for each of the serotypes. Both AAV4 and AAV5 had elevated (eight-and fourfold, respectively) NAB titers compared with AAV2 ( Figure 4 ). No activity was found in sera of untreated Submandibular glands infused with rAAV2-, rAAV4-, or rAAV5-expressing GFP were removed after 6 weeks, sectioned, and analyzed by histochemical staining for GFP expression. In all, 40 fields of strongly stained (hot spots) areas were selected from each sample. All the cells present in each of the selected fields were counted and the number of GFP-positive cells expressed as a percentage of the cells in the duct (positive cells/duct). Striated, excretory, and intercalated ducts were positive with each isolate but for the purpose of quantitation were not distinguished. 
AAV neutralizing activity in saliva
In addition to serum, antibodies also are found in saliva and other mucosal secretions. Therefore, the saliva of AAV-infused mice also was assayed for neutralizing activity. While secretory IgA could be detected in the saliva samples, no antibody-mediated inhibitory activity was detected for AAV2, 4 and 5 (data not shown). However, at low dilutions of saliva we observed a dosedependent decrease in AAV4 transduction but not AAV2 or AAV5 (Figure 5a ). This inhibitory activity was also detected in the saliva of control, noninfused mice suggesting that inhibition was the result of the innate protective properties of saliva and not the result of exposure to the virus. Our previous work had demonstrated that mucins produced by lung epithelia contain large amounts of O-linked sialic acid and are inhibitory to AAV4 transduction but not to AAV5 transduction.
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To further understand the salivary inhibition of AAV4, saliva of rAAV4-infused mice was treated with neuraminidase to remove sialic acid prior to the assay. Following neuraminidase treatment, the inhibitory activity in saliva was no longer detected ( Figure 5b ). Furthermore, neuraminidase treatment also removed the inhibitory activity observed in preimmune saliva from the naive animals. These results suggest that as with lung epithelia, the inhibitory activity is related to innate Figure 3 Biodistribution of rAAV2, rAAV4, and rAAV5. Genomic DNA was isolated from salivary glands, liver, and lung of both infused and control mice (n ¼ 3 each). All infused mice tested positive for b-galactosidase expression prior to QPCR. QPCR was performed using primers specific to the RSV promoter in the transgene cassette. 
Discussion
In the present study, we examined salivary gland cell transduction with rAAV2, rAAV4, and rAAV5 vectors following administration to mouse submandibular salivary glands by retrograde ductal infusion. We observed distinct transduction characteristics for all three vectors. Our results with rAAV2bgal were similar to prior reports. 8, 9, 22 However, we demonstrated improved transduction activity and altered tropism with AAV5 and AAV4, respectively. In both the transduction and the tropism experiments, the vectors contained identical gene cassettes (RSV-LacZ and CMV-GFP, respectively). Thus, differences in transduction and tropism among these three vectors maybe attributed to variations in their capsids. The low bgal activity noted in two AAV5-infused animals is likely the result of poor delivery and not an adverse response to the vector. No such variability in transduction was observed within the group of mice infused with AAV5 GFP.
Several reports show that different serotypes of rAAV can have distinct patterns of cell tropism and distribution in a tissue. 11, 12, 14, 29 These differences in tropism and transduction are primarily due to differences in the interactions with the target cells but also related to anatomical barriers that exist within the tissue that may limit optimal virus spread. Efficient AAV2 transduction requires expression of HSPG on the target cell surface. In epithelia such as the lung, HSPGs are primarily found on the basolateral surface. 30 Characterization of the cellular components required for transduction with AAV4 and AAV5 demonstrate that both serotypes preferentially bind to a2-3 sialic acid residues, but differ in their linkage specificity. In addition, PDGFRa or PDGFRb have been identified as protein receptors for AAV5 and their expression correlates with transduction in vivo. 21 Although sialic acid expression on salivary gland cells has not been investigated, we have detected PDGFRa expression on the surface of ductal cells, which is associated with the tropism observed (Figure 2h ). In the lung, PDGFRa is primarily found on the apical surface 31 and if the polarization is the same in salivary gland epithelia, would present a more accessible target for transduction and result in improved transduction compared with AAV2.
Salivary mucins of mice are reported to contain a2-3 O-linked sialic acid. 32 The inhibition of AAV4 by sialic acid-containing components of the saliva is in agreement with this report, as well as with our previous work regarding the affect of mucins produced by lung epithelia. This observation also suggests that removal of saliva from the gland lumen prior to AAV4 infusion may further improve transduction.
At 1-month postinfusion, the vast majority of persistent AAV genomes with all three serotypes were found in the gland and not the liver or lung. The increase transduction activity of AAV4 and AAV5 is likely to limit the amount of vector available to spread to other tissue and increase their relative localization compared with AAV2. Alternatively, it is also possible that AAV2 is spreading to other tissues not assayed in this study.
In contrast, infusion of adenovirus into salivary glands resulted in transient widespread distribution of vector. 23 This distinction indicates a fundamental difference in the interaction between AAV and adenoviral vectors with these glands and suggests that in contrast to AAV, adenovirus infusion or the immune response to the vector may disrupt cellular junctions within the gland thus allowing access to the circulation.
While a higher NAB response was observed with AAV4 and AAV5 vectors compared with AAV2, it is not clear if this is a result of the intrinsic antigenicity of the AAV4 and AAV5 capsids compared with AAV2 or the lower transduction activity of these two serotypes in the cell line-based assay used to detect the presence of NABs compared with AAV2. Alternatively, the increased antibody titer may reflect the increased transduction activity in the gland of these vectors compared with AAV2. Additional studies will be required to determine if AAV4 or AAV5 induce a distinct innate or cellular immune response compared with AAV2.
Interestingly anti-rAAV NABs were detected in serum following salivary gland administration, but not in saliva. In contrast, infusion of adenoviral vector, results in elevated serum antiadenovirus immunoglobulin G (IgG) and IgM levels and antiadenovirus IgA levels in saliva. 33 The salivary glands are normally protected by both the mucosal and the systemic immune system. However, recently reported data suggest that serum antibodies may prohibit salivary gland transduction for over 1 month following readministration of the same serotypes of AAV. 7 The lack of crossreactive antibodies further suggests that transduction maybe possible with an alternative serotype of AAV. 34, 35 The salivary glands are an excellent target for delivery of therapeutic proteins to the oral cavity and upper gastrointestinal tract because of their natural exocrine function, but also maybe useful for delivery to the systemic circulation via their endocrine activity. 2, 36 Our recent demonstration of long-term endocrine expression of erythropoetin from the glands with AAV2 vectors further highlights their utility as a depot organ for systemic protein delivery. 9, 37 The increased transduction with AAV5 suggests that enhanced gene expression is possible or that comparable levels of expression could be achieved with a lower dose of vector, a potentially important safety consideration. In contrast to adenovirus, none of the AAV vectors tested in this study could transduce acinar cells. Owing to their central role in saliva production, they represent a major therapeutic target. Other isolates, such as AAV6-AAV11, have been studied for their transduction, tropisms, and crossneutralizing activities in a number of systems. 38, 39 Results suggest they may have distinct transduction activities compared to the isolates tested in this study. Therefore, it will be important to test other isolates of AAV for their ability to mediate transduction of acinar cells in future studies.
Materials and methods
Cell culture, plasmids, and AAV vector production Cos cells were maintained as monolayer cultures in D10 medium (Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U of penicillin/ml, Enhanced transduction of mouse salivary glands H Katano et al 100 U of MSG streptomycin/ml, and 2.5 U of Fungizone) as recommended by the manufacturer (Biofluids, Rockville, MD, USA). Recombinant AAV vectors expressing bgal, AAV2bgal, AAV 4bgal, and AAV 5bgal, or GFP, were prepared by cotransfection of 293T cells as previously described. 20 Vectors for this study were purified using CsCl gradient centrifugation. 40 
Animals
BALB/c mice used in this study were maintained in the animal facilities of the National Institute of Dental and Craniofacial Research (NIDCR). Animal protocols were approved by NIDCR Animal Care and Use Committee and the National Institutes of Health (NIH) Biosafety committee. All procedures were conducted in accordance with IASP (International Association for the Study of Pain) standards.
rAAV vector administration into mouse salivary glands
Vectors were delivered into submandibular glands by retrograde ductal administration as previously described. 8, 22, 41 Briefly, male mice (7 weeks old) were anesthetized with ketamine (60 mg/ml, 1 ml/g body weight; Phoenix Scientific, St Joseph, MO, USA) and xylazine (8 mg/ml; Phoenix Scientific), by i.m. injection, then administered atropine (0.5 mg/kg body weight, i.m.; Sigma, St Louis, MO, USA) to reduce salivary flow. After 10 min, 50 ml of rAAV vector, 10 10 viral particles in isotonic saline, was infused through a tapered cannula inserted into an orifice of the main excretory duct.
At 4 weeks after vector administration, the mice were anesthetized to collect saliva by subcutaneous injection with pilocarpine (0.5 mg/kg body weight). Whole saliva accumulated in the oral cavity was collected with a capillary tube as previously described. 8, 22, 41 Blood was collected from the animals by retro-orbital plexus bleeding, from which serum was separated by centrifugation. Submandibular glands, as well as liver and lung, were carefully dissected from the animals, and were treated appropriately, as described below.
ELISA for bgal
Whole submandibular glands were minced with scalpel blades, and prepared as tissue lysates by homogenization with 500 ml of Galact-light lysis solution (100 mM potassium phosphate (pH 7.8), 0.2% Triton X-100) (Applied Biosystems, Foster City, CA, USA) supplemented with phenylmethylsulfonyl fluoride (0.2 mM) and leupeptin (5 mg/ml). The crude lysates were centrifuged at 10 000 r.p.m. for 5 min, and protein in the supernatant was used for assays. Levels of bgal in rAAV-transduced mouse submandibular glands were determined with a bGal ELISA kit (Roche Applied Science, Indianapolis, IN, USA). The levels were standardized by total protein concentration, determined by using BCA protein assay kit (Pierce Biotechnology Inc., Rockford, IL, USA) and are shown as picograms of bgal per milligram of protein.
Quantification of AAV vector
Genomic DNA of the salivary glands was extracted from 100 ml of the crude lysates (see above) using the Wizard DNA extraction kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions, and rehydrated in 20 ml of provided buffer. Total DNA concentrations were quantified by spectrophotometry and were standardized with buffer to be 100 ng genomic DNA/ml. Of the lysate, 1 ml (100 ng genomic DNA) was added to 24 ml of PCR reaction mix containing 1 Â SYBR Green master mix (Applied Biosystems, Foster City, CA, USA), 0.32 pmol/ml of primers specific to the Rous sarcoma virus (RSV) promoter and amplification was performed with an ABI PRISM 7700 sequence detection system (Applied Biosystems). The forward primer 5 0 -GATGAGTTAGCAACATGCCTTACAA, reverse primer 5 0 -TCGTACCACCTTACTTCCACCAA. Following a 951C, 10 min denaturing step, cycling conditions were 951C for 15 s, and 601C for 1 min for 40 cycles. The vector DNA in each sample was quantified by comparing the fluorescence profiles with a set of DNA standards, pAAVRSV, containing 100 ng genomic DNA extracted from glands of an untreated mouse. Additionally, liver and lung (10-20 mg, n ¼ 3, each) were prepared as tissue lysates in a manner similar to salivary glands, and from which genomic DNA was extracted as described above. Amount of vector DNA in each sample was measured using DNA standards supplemented with 100 ng genomic DNA extracted from corresponding tissues of a control mouse.
Histological/immunohistochemical analysis
At 6 weeks after cannulation and delivery of AAV vectors encoding GFP to murine salivary glands, the animals were killed and the salivary glands removed. The transgene expression was detected by immunohistochemical analyses. 37 Immunohistochemistry was performed in formalin-fixed sections (5-mm thick) using the streptavidin-biotin peroxidase complex method. Briefly, after endogenous peroxidase, streptavidin and biotin activity were blocked (Streptavidin/Biotin Blocking Kit SP-2002, Vector Laboratories; Burlingame, CA, USA), sections were incubated with a polyclonal primary antibody against GFP (AB 290; ABCAM, Cambridge, UK) raised in rabbit, at a dilution of 1:100, overnight at 41C. Staining was developed by using a biotinylated goat antibody (Vector Laboratories) directed against the primary antibody and the avidin-biotin peroxidase complex followed by diaminobenzidine (SK-4100; Vector laboratories) and counterstained with hematoxylin.
Serum neutralizing antibody assay
Exponentially growing Cos cells (7 Â 10 3 ) were plated in each well of a flat-bottomed 96-well plate. After 1 day they were infected for 1 h with wild-type adenovirus at a multiplicity of infection of 10, the medium was removed, and antibody-virus mixture was added. The antibodyvirus mixture was prepared by first heat inactivating the sera at 561C for 30 min. Twofold serial dilutions of the sera were then prepared starting at a 1:50 dilution in media containing 1% FCS as the diluent. Diluted rAAV vectors sufficient to transduce 10-30 cells/well was then added to the sera and incubated for 1 h at 371C. The antibody-virus mixture was then added to the cells and incubated for 30 h at 371C before fixing and stained for bgal activity 24 h at 371C with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (Gold BioTechnology Inc., St Louis, MO, USA). 20 Transduced cells were visually counted using a light microscope. Neutralizing titers of the sera ware calculated as the highest dilution that inhibited 50% of transduction. Any serum dilution that had a 470% reduction in the number of Enhanced transduction of mouse salivary glands H Katano et al positive cells compared with serum-free media remained was considered to be positive for neutralizing activity. All samples were assayed in duplicate or triplicate.
Saliva neutralizing antibody assay
Instead of sera, twofold dilutions of saliva, from 1/12.5 to 1/200, were tested for neutralizing activity described above. Saliva-free media was used as a control. Transduction rates were calculated as the percentage of the transduced cells in each well divided by that in the control well, and the rates at dilutions of 1/12.5 and 1/200 are presented.
Neuraminidase treatment of saliva
To remove sialic acid, saliva was treated with neuraminidase at 371C for 1 h, following which the enzyme was inactivated at 561C for 30 min, and tested for neutralizing activity. The transduction rates of neuraminidase-treated and -untreated saliva were compared at a dilution of 1/12.5. Salmonella typhimutium neuraminidase was purchased from Glyko (Novato, CA, USA).
Statistical analysis
Descriptive statistics were calculated and reported as means7s.d. The Student's t-test for unpaired variables was used to compare differences between groups, P-values p0.05 were considered significant.
